Source comparison
CJC-1295 Extended Half-Life: Research Application Comparison
CJC-1295 with DAC 6–8 days Once per week Yes. Covalent albumin binding via maleimidopropionyl linker Sustained GH elevation studies, long-term metabolic research, pharmacokinetic modelling 28 days at 2–8°C; DAC linker degrades rapidly above 8°C Uniquely suited
This comparison does not assign a generated winner or score.
- CJC-1295 with DAC
- 6–8 days
- Once per week
- Yes. Covalent albumin binding via maleimidopropionyl linker
- Sustained GH elevation studies, long-term metabolic research, pharmacokinetic modelling
- 28 days at 2–8°C; DAC linker degrades rapidly above 8°C
- Uniquely suited for extended half-life studies requiring stable plasma levels across multi-day intervals. No alternative GHRH analogue achieves comparable retention
- Modified GRF 1-29 (CJC-1295 no DAC)
- <30 minutes
- Every 3–4 hours
- No
- Pulsatile GH release studies, acute receptor occupancy experiments
- 28 days at 2–8°C; structurally stable but requires frequent dosing
- Ideal for short-duration studies where rapid clearance is desirable. Not viable for extended half-life research
- Sermorelin
- <10 minutes
- Every 2–3 hours
- Acute GH pulse measurement, diagnostic GH reserve testing
- 28 days at 2–8°C; highly susceptible to DPP-IV degradation
- Shortest half-life of clinical GHRH analogues. Useful only for single-dose or immediate-response protocols
- Tesamorelin
- ~45 minutes
- Daily
- No. Trans-3-hexenoic acid modification provides modest stability improvement
- HIV-associated lipodystrophy research, GH deficiency studies
- 28 days at 2–8°C; slightly more stable than sermorelin but still requires daily dosing
- Moderate half-life extension compared to unmodified GHRH, but insufficient for multi-day protocols